Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Day One Biopharmaceuticals Inc shares valued at $163,417 were sold by Bender Jeremy on May 03 ’24. At $17.85 per share, Bender Jeremy sold 9,154 shares. The insider’s holdings dropped to 642,602 shares worth approximately $10.53 million following the completion of this transaction.
Also, York Charles N II sold 8,078 shares, netting a total of over 144,214 in proceeds. Following the sale of shares at $17.85 each, the insider now holds 217,293 shares.
Before that, York Charles N II had sold 200 shares from its account. In a trade valued at $3,579, the COO, CFO AND SECRETARY traded Day One Biopharmaceuticals Inc shares for $17.90 each. Upon closing the transaction, the insider’s holdings decreased to 200 shares, worth approximately $3.69 million.
As published in a research note from Needham on April 24, 2024, Day One Biopharmaceuticals Inc [DAWN] has been retained to a Buy and the price target has been revised to $33. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”an Underperform”‘ outlook in a report released in late April. As of February 08, 2023, CapitalOne has initiated its “an Overweight” rating for DAWN. Earlier on February 03, 2023, Oppenheimer initiated its rating. Their recommendation was “a Perform” for DAWN stock.
Analyzing DAWN Stock Performance
During the last five days, there has been a drop of approximately -6.77%. Over the course of the year, Day One Biopharmaceuticals Inc shares have jumped approximately 12.19%. Shares of the company reached a 52-week high of $18.07 on 05/01/24 and a 52-week low of $13.02 on 04/25/24. A 50-day SMA is recorded $15.45, while a 200-day SMA reached $13.79. Nevertheless, trading volume fell to 0.68 million shares from 1.78 million shares the previous day.
Support And Resistance Levels for Day One Biopharmaceuticals Inc (DAWN)
According to the 24-hour chart, there is a support level at 16.11, which, if violated, would cause prices to drop to 15.85. In the upper region, resistance lies at 16.79. The next price resistance is at 17.21. RSI (Relative Strength Index) is 52.96 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.35, which suggests the price will decrease in the coming days. Percent R is at 33.46%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Day One Biopharmaceuticals Inc (DAWN)?
On December 15, 2022, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $35.
